Lastname    Password   

The largest participative network on microencapsulation

3th Latin-America Symposium on Microencapsulation

Pucon, Chile
November 27-29, 2017

More information, click here

21th Microencapsulation Industrial Convention

Montreal, Canada
May 21-24, 2018

More information, click here

10th Training School on Microencapsulation

Throndheim, Norway
September 2018

More information, available in January

Microencapsulation News


Publ. : 22 NOV. 2017 - Deadline : 22 FEB. 2018
Beta-lactoglobulin and lactoferrin complex coacervates for the encapsulation of a model bioactive, the vitamin B9?

Date : 26 of October 2017 Place : Laboratoire Sciences et Technologie du Lait de l'Oeuf, Agrocampus Ouest, Rennes, France Functional foods are a s bject of growing interest today, motivated by their potential to prevent diseases and contribute to healthier daily lifestyles. Encapsulation of bioactives represents a great potential for the development of such products, with enhanced health benefits. Given the food industry’s desire to develop and promote a “clean label”, the use of food proteins as encapsulating agents appears to be relevant. In parallel, whey proteins (WP), co-products of the dairy industry, exhibit good potentialities for use as encapsulating agents that could in fine enhance their functional and economic value. Moreover, previous works have demonstrated that the two WPs, beta-lactoglobulin (BLG) and lactoferrin (LF), are able to spontaneously co-assemble by complex coacervation, a known encapsulation technology. In that context, this study aims to explore BLG and LF complex coacervation for the encapsulation of a model bioactive, vitamin B9. A series of experiments have made it possible to establish the domains of B9-LF-BLG coacervation according to a tested range of pH, proteins and vitamin molar ratios. In our study, optimal conditions for B9-WP coacervation were found in water, at pH 5.5, with a LF:B9:BLG molar ratio of 1:5:10, to obtain WP coacervation yields of between 45 to 55% and B9 encapsulation up to 98%. WP complex coacervation was then scaled-up from the laboratory to the bench scale using commercial-grade protein solutions and static mixing. Final efficiencies, similar to the laboratory scale, were reached, allowing the production of B9-WP coacervates containing 4 mg of B9/g WP coacervates. Under degradative conditions in vitro (UV light irradiation, oxidation by H2O2, freeze-drying), WP coacervates demonstrated good protective properties to limit chemical degradations of B9. Moreover, in vivo oral administration of B9-WP coacervates in rats made it possible to enhance the plasmatic concentrations of the vitamin compared to oral administration of unencapsulated B9. B9-WP coacervates also showed good physical stability over time when incorporated into milk in the form of small droplets suspended in solution. The combined results of this thesis provide a better insight into heteroprotein complex coacervation, attempting to link the theory behind this long-established chemical concept to its potential interest for innovative applications.

More information

Industrial Convention
Publ. : 06 NOV. 2017 - Deadline : 21 MAY 2018
21st Microencapsulation Industrial Convention - Montreal, Canada - May 21-24, 2018

We are please to invite you to register for the next 21st Microencapsulation Industrial Convention. A combination of expert presentations, exhibitions and a business to business trade fair (hundreds of individual meetings). Register soon to get low registration fees and get an exceptional accommodation rate at the 4 starts convention hotel.

More information

Training School
Publ. : 06 NOV. 2017 - Deadline : 30 SEPT. 2018
10TH training school on microencapsulation - Throndheim, Norway - September 2018

The 10TH training school on microencapsulation will focuse on heath applications of microencapsulation. It will be held in Throndheim, Norway in Septe ber 2018. The web site will be open in January 2018

More information

Publ. : 02 OCT. 2017 - Deadline : 27 AUG. 2018
BIOBARRIERS 2018 - 27 – 29 August 2018 in Saarbrücken, Germany

The 12th International Conference and Workshop on Biological Barriers is an international scientific event, organized every two years and receiving co stantly 200+ registered attendees from all over the world. In the focus of BioBarriers 2018 are human cell and tissue models for facilitating clinical translation of new drugs and delivery systems, especially in the context of infectious diseases. Moreover, we will discuss innovative concepts and materials, also capable to overcome non-cellular diffusion barriers such as mucus or bacterial biofilms, concluding the conference with sessions on extracellular vesicles and advanced nanomedicines for non-invasive delivery of macromolecular biopharmaceuticals. Target audiences are early stage researchers as well as experienced scientists and professionals from academia and the pharmaceutical industry.

More information

Publ. : 01 OCT. 2017 - Deadline : 01 DEC. 2017
Microencapsulated lipid nanoparticles for pulmonary delivery of biopharmaceutical agents

Thesis 2017 by Diana Patricia Rodrigues Gaspar UNIVERSIDADE DE LISBOA FACULDADE DE FARMÁCIA A key point in the administration of biopharmaceutica s is the recognition of appropriate, effective, safe and biocompatible nanocarriers allowing overcoming extracellular and intracellular biological barriers without loss of drug stability and adequate therapeutic response at the target sites. Since their description by Rainer Müller in the early 1990’s, solid lipid nanoparticles (SLN) have been developed as an effective colloidal drug carrier. Under optimized conditions, SLN can be produced for the entrapment of lipophilic or hydrophilic drugs with the essential requirements for an optimum nanoparticulate carrier. Its colloidal size and the controlled release behaviour allow protection and management when administered by parenteral and non-parenteral routes (e.g., oral, nasal and pulmonary). The pulmonary route has gained interest to the non-invasive administration of biopharmaceuticals on account of the promising anatomical features of the lung, particularly its large absorptive epithelial surface area, low thickness and avoiding the first-pass effect. The lung region where the particles are deposited depends on their aerodynamic diameter. The complex structure of the respiratory tree and the natural defence mechanisms of the lung are fundamental aspects for the design of a proper pulmonary delivery system. Although pulmonary delivery of nanoparticles has an unquestionable interest, it still requires a complex setup and an aerosolization technique, due to their low inertia and small size, which hindering the deposition in the lung, facilitating the exhalation with air. A promising alternative is the formulation of nanoparticles in inhalable microspheres that ensure their release after pulmonary administration. Microspheres have recently been proposed for pulmonary inhalation as dry powders, since they can be designed to achieve appropriate morphological and aerodynamic characteristics. Previous studies have shown that polymeric nanocarriers loaded in microparticulate systems present a great potential for pulmonary delivery of therapeutic macromolecules and genetic material. These microspheres act only as inert vehicles of the nanoparticles, which remain unaltered after the spray-drying process, not affecting the properties or the release profile of the encapsulated active agents, thus constituting a suitable microparticulate carrier for the pulmonary delivery of drug-containing nanoparticles

More information

Publ. : 06 AUG. 2017 - Deadline : 26 NOV. 2017
3rd Latin-America Symposium on Microencapsulation - Pucon, Chile - November 27-29, 2017

The third Latin America Symposium on Microencapsulation will be held in Pucon, Chile on November 27-29, 2017. Three days of opportunities to meet rese rchers from Latin America but also some invited speakers from different countries and establish new collaborations.

More information

Send information to be included in the news to

including a short title, a description of 5-10 lines, a deadline, a link (email or url), your name
We ask you before to send your request to register on the BRG